However, the stock could see gains in the medium term. The stock is down by about -16% year-to-date. The stock has remained almost flat year-to-date, due to mixed quarterly earnings and some headwinds due to Covid-19. The stock is down by about -2% year-to-date, due to mixed quarterly earnings and some headwinds due to Covid-19. That said, the worst is likely behind EBS stock now with the company recently noting that it was rectifying the issues, with production likely to resume within days. Considering the current pandemic and the shortage of vaccines globally, its likely that demand for the companys services will hold up.
The stock is up by about +16% year-to-overage.
( z0 up :ARG1 ( z1 stock ) :ARG2 ( z2 about :op ( z3 product-of :op ( z4 percentage-entity :value "+16" ) :op ( z5 overage :mod ( z6 year ) ) ) ) )
(z0 / up-02
    :ARG1 (z1 / stock)
    :ARG2 (z2 / about
              :op1 (z3 / product-of
                       :op1 (z4 / percentage-entity
                                :value "+16")
                       :op2 (z5 / overage
                                :mod (z6 / year)))))
The stock is up by about +16 % year - to - overage .
z0 :ARG1 z1
z0 :ARG2 z2
z2 :op1 z3
z4 :value 0
z3 :op1 z4
z5 :mod z6
z3 :op2 z5